Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2019-11-06 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Freeline presents pre-clinical data at ASH meeting
Regulatory Filings Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content is an announcement by Syncona Limited regarding its portfolio company, Freeline, presenting pre-clinical data at the American Society of Hematology (ASH) annual meeting. This is a general regulatory announcement concerning corporate news and scientific updates, not a comprehensive financial report (like 10-K or IR) or a specific management/director filing. Since it is a general regulatory announcement distributed via the RNS system and doesn't fit the more specific categories like ER, DIV, or DIRS, the appropriate classification is Regulatory Filings (RNS). The document length is moderate, but the primary identifier is the RNS header and context.
2019-11-06 English
Syncona cornerstones £100m financing in Achilles
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It details a specific corporate financing event where Syncona Limited committed £100 million to Achilles Therapeutics. This falls under the category of capital and financing updates, as it describes fundraising activities and changes to the company's investment portfolio and capital structure.
2019-09-03 English
Syncona makes £48 million commitment to Gyroscope
Share Issue/Capital Change Classification · 99% confidence The document begins with an 'RNS Number' and is dated September 3, 2019. The content details a significant financial commitment (£48 million Series B financing) by Syncona Limited into Gyroscope Therapeutics. This type of announcement, detailing corporate financing, investment, or material business updates released via the London Stock Exchange's RNS system, fits best under the general 'Regulatory Filings' category, as it is not a full annual report (10-K), an earnings release (ER), or a specific capital change like a share buyback (POS). While it relates to capital, it is an investment/financing announcement, which is often captured by RNS if a more specific code like CAP (Capital/Financing Update) is not used for general press releases of this nature. Given the explicit mention of 'RNS Number' and the nature of the announcement (a material corporate event update), RNS is the most appropriate general regulatory filing code, although CAP is a close secondary candidate. Since RNS is defined as the fallback for miscellaneous regulatory filings, and this is a standard corporate news release format distributed via RNS, I will select RNS.
2019-09-03 English
Quarterly Update
Regulatory Filings Classification · 98% confidence The document is explicitly labeled with "RNS Number : 6363I" and contains a section titled "National Storage Mechanism | Additional information". It provides a "Quarterly Update" for the period ending June 30, 2019, detailing financial milestones, portfolio company progress, and capital deployment. This content structure—a periodic update on performance and portfolio—aligns closely with an Interim/Quarterly Report (IR). However, the document is distributed via RNS, which is the news service of the London Stock Exchange, and it is a summary announcement rather than the comprehensive financial statements typically found in a full IR filing. Since it is a periodic update announcement distributed through the regulatory news service, and it is not a full 10-Q equivalent, it fits best as an Interim/Quarterly Report (IR) because the content is substantive financial and operational reporting for a period shorter than a year, not just a notice that a report is available (which would be RPA/RNS). The key phrase is "Syncona Limited... today issues its quarterly update covering the period from 1 April to 30 June 2019."
2019-08-12 English
Autolus reports Q2 2019 Financial Results
Earnings Release Classification · 99% confidence The document is an RNS announcement from Syncona Limited, dated August 8, 2019, noting that its portfolio company, Autolus Therapeutics Plc, is reporting its 'second quarter 2019 financial results and operational progress'. The text includes key financial highlights (cash, expenses, net loss for the three and six months ended June 30, 2019) and operational updates, followed by the full text of Autolus' announcement, which contains condensed unaudited statements of operations. This structure—a brief announcement referencing the release of detailed financial results for a specific period (Q2 2019)—is characteristic of an Earnings Release (ER). Although it contains financial tables, the primary context is the announcement of the results, not the comprehensive annual filing (10-K) or a standalone interim report (IR) which would typically be filed with a regulator like the SEC, rather than being disseminated via RNS as an initial release. Since it explicitly announces the 'Financial Results' for a period, ER is the most appropriate code. It is not a Call Transcript (CT) as it lacks Q&A structure, nor is it a Report Publication Announcement (RPA) because it contains the substance of the results, not just a notice that a report is available. Q2 2019
2019-08-08 English
Completion of sale of Blue Earth Diagnostics
Regulatory Filings Classification · 99% confidence The document is a short announcement dated August 1, 2019, identified by the 'RNS Number : 4709H' header. It details the 'Completion of sale of Blue Earth Diagnostics' and provides financial figures related to the transaction. The presence of the RNS identifier and the nature of the content (a brief corporate event announcement, not a full financial report or presentation) strongly suggests it is a regulatory news service release. Since it is a general regulatory announcement that doesn't fit specific categories like DIV, CAP, or M&A (though it relates to a transaction, it's the announcement of the completion, not the proposal), the most appropriate classification is the general regulatory filing category, RNS, especially given the explicit mention of RNS at the end.
2019-08-01 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.